HDAC 8 INHIBITOR FOR TREATMENT OF CANCER

Title:

HDAC 8 INHIBITOR FOR TREATMENT OF CANCER

Document Type and Number:

Japanese Patent JP2019194194

Kind Code:

A

Abstract:

To provide a compound for inhibiting HDAC 8.SOLUTION: There is provided a compound of the formula 1. In the formula, A is aryl, heteroaryl or the like; X is -C(R)= or -N=; Ris H, halogen, or the like; Y is a bond, -O-, -S-, or the like; Lis a bond, -O-, substituted or unsubstituted alkylene or the like; Ris halogen, substituted or unsubstituted alkyl or the like; Ris halogen, substituted or unsubstituted C1 to C5 alkyl or the like; Ris independently H, substituted or unsubstituted C1 to C5 alkyl or the like; m1 is 0, 1, 2, 3 or 4; m2 is 0, 1, 2, 3, 4, 5 or 6; and m3 is 0, 1 or 2.SELECTED DRAWING: None

More Like This:

JPH09221420	SUSTAINED RELEASE AGENT OF HYDROXAMIC ACID COMPOUND
JP3922431	Hydroxamic acid derivative as a soluble human CD23 formation inhibitor
JP2002508361	INDUSTRIAL APPLICABILITY: ((Cyclo) alkyl substitution)-γ-aminobutyric acid derivative (= GABA analog), their production and use in the treatment of neurological diseases.

Inventors:

KUO YA HUEI
HUANG WEI-JAN
CHUNG I-CHUNG

Application Number:

JP2019104362A

Publication Date:

November 07, 2019

Filing Date:

June 04, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

HOPE CITY
UNIV TAIPEI MEDICAL
ACADEMIA SINICA

International Classes:

C07C259/06; A61K31/16; A61K31/343; A61K31/36; A61K31/381; A61K31/404; A61K31/44; A61K31/47; A61K31/472; A61K31/713; A61K38/16; A61K39/395; A61K45/00; A61K48/00; A61P35/00; A61P35/02; A61P43/00; C07D213/74; C07D215/14; C07D217/16; C07D307/91; C07D317/60; C07D333/24

Domestic Patent References:

JP2016530273A	2016-09-29
JP2011020999A	2011-02-03
JP2008509075A	2008-03-27

Foreign References:

WO2013101600A1

2013-07-04

Attorney, Agent or Firm:

Kawaguchi International Patent Office

Previous Patent: 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Next Patent: 抗ＰＤＬ１抗体製剤